MAPKs and NF‑κB pathway inhibitory effect of bisdemethoxycurcumin on phorbol‑12‑myristate‑13‑acetate and A23187‑induced inflammation in human mast cells

Kong,Ryong; Kang,Ok‑Hwa; Seo,Yun‑Soo; Zhou,Tian; Kim,Sang‑A; Shin,Dong‑Won; Kwon,Dong‑Yeul

doi:10.3892/mmr.2017.7852

MAPKs and NF‑κB pathway inhibitory effect of bisdemethoxycurcumin on phorbol‑12‑myristate‑13‑acetate and A23187‑induced inflammation in human mast cells

Authors:
- Ryong Kong
- Ok‑Hwa Kang
- Yun‑Soo Seo
- Tian Zhou
- Sang‑A Kim
- Dong‑Won Shin
- Dong‑Yeul Kwon
View Affiliations

Affiliations: Department of Oriental Pharmacy, College of Pharmacy, Wonkwang Oriental Medicines Research Institute, Wonkwang University, Iksan, Jeonbuk 54538, Republic of Korea, Department of Oriental Medicine Resources, College of Bio Industry Science, Sunchon National University, Sunchon, Jeonnam 57922, Republic of Korea
Published online on: October 20, 2017 https://doi.org/10.3892/mmr.2017.7852
Pages: 630-635

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Inflammation‑associated damage may occur in any tissue following infection, exposure to toxins, following ischemia, and in allergic and auto‑immune reactions. Inflammation may also result from mast cell degranulation induced by the intracellular calcium concentration. The inflammatory process may be inhibited by compounds that affect mast cells. Bisdemethoxycurcumin [1,7‑bis(4‑hydroxyphenyl) hepta‑1,6‑diene‑3,5‑dione, BDCM] is the active component of turmeric. It has anticancer, antioxidant and antibacterial properties. To investigate the molecular mechanism associated with the anti‑inflammatory activity of BDCM, human mast cell line 1 (HMC‑1) cells were treated with phorbol‑12‑myristate‑13‑acetate (PMA) and calcium ionophore A23187 (A23187) to induce the inflammatory process. Various HMC‑1 cells were pretreated with BDCM prior to stimulation of inflammation. BDCM inhibited the inflammation‑triggered production of cytokines including interleukin (IL)‑6, IL‑8, and tumor necrosis factor (TNF)‑α. BDCM inhibition extended to the gene level. In activated HMC‑1 cells, phosphorylation levels of extracellular signal‑regulated kinase, c‑jun N‑terminal kinase and p38 mitogen‑activated protein kinase were decreased by treatment with BDCM. BDCM also inhibited nuclear factor‑(NF)‑κB activation and IκB degradation. In conclusion, BDCM suppresses the expression of TNF‑α, IL‑8, and IL‑6 by inhibiting the NF‑κB and mitogen activated protein kinase signaling pathways.

View Figures

View References

1	Jeong HJ, Na HJ, Kim SJ, Rim HK, Myung NY, Moon PD, Han NR, Seo JU, Kang TH, Kim JJ, et al: Anti-inflammatory effect of Columbianetin on activated human mast cells. Biol Pharm Bull. 32:1027–1031. 2009. View Article : Google Scholar : PubMed/NCBI
2	Galli SJ, Zsebo KM and Geissler EN: The kit ligand, stem cell factor. Adv Immunol. 55:1–96. 1994. View Article : Google Scholar : PubMed/NCBI
3	Metcalfe DD, Baram D and Mekori YA: Mast cells. Physiol Rev. 77:1033–1079. 1997.PubMed/NCBI
4	Yoo JM, Yang JH, Kim YS, Yang HJ, Cho WK and Ma JY: Inhibitory effects of viscum coloratum extract on IgE/antigen-activated mast cells and mast cell-derived inflammatory mediator-activated chondrocytes. Molecules. 22:pii: E37. 2016. View Article : Google Scholar : PubMed/NCBI
5	Spalinger MR, McCole DF, Rogler G and Scharl M: Protein tyrosine phosphatase non-receptor type 2 and inflammatory bowel disease. World J Gastroenterol. 22:1034–1044. 2016. View Article : Google Scholar : PubMed/NCBI
6	Hamawy MM, Mergenhagen SE and Siraganian RP: Protein tyrosine phosphorylation as a mechanism of signalling in mast cells and basophils. Cell Signal. 7:535–544. 1995. View Article : Google Scholar : PubMed/NCBI
7	Petrou T, Olsen HL, Thrasivoulou C, Masters JR, Ashmore JF and Ahmed A: Intracellular calcium mobilization in response to ion channel regulators via a calcium induced calcium release mechanism. J Pharmacol Exp Ther. 360:378–387. 2017. View Article : Google Scholar : PubMed/NCBI
8	Crossthwaite AJ, Hasan S and Williams RJ: Hydrogen peroxide-mediated phosphorylation of ERK1/2, Akt/PKB and JNK in cortical neurones: Dependence on Ca (2+) and PI3-kinase. J Neurochem. 80:24–35. 2002. View Article : Google Scholar : PubMed/NCBI
9	Wong CK, Tsang CM, Ip WK and Lam CW: Molecular mechanisms for the release of chemokines from human leukemic mast cell line (HMC)-1 cells activated by SCF and TNF-alpha: Roles of ERK, p38 MAPK, and NF-kappaB. Allergy. 61:289–297. 2006. View Article : Google Scholar : PubMed/NCBI
10	Li L, Zhang XH, Liu GR, Liu C and Dong YM: Isoquercitrin suppresses the expression of histamine and pro-inflammatory cytokines by inhibiting the activation of MAP Kinases and NF-κB in human KU812 cells. Chin J Nat Med. 14:407–412. 2016.PubMed/NCBI
11	Cagnol S and Chambard JC: ERK and cell death: Mechanisms of ERK-induced cell death-apoptosis, autophagy and senescence. FEBS J. 277:2–21. 2010. View Article : Google Scholar : PubMed/NCBI
12	Zhao J, Wang L, Dong X, Hu X, Zhou L, Liu Q, Song B, Wu Q and Li L: The c-Jun N-terminal kinase (JNK) pathway is activated in human interstitial cystitis (IC) and rat protamine sulfate induced cystitis. Sci Rep. 6:196702016. View Article : Google Scholar : PubMed/NCBI
13	Zhou Y, Yang Q, Xu H, Zhang J, Deng H, Gao H, Yang J, Zhao D and Liu F: miRNA-221-3p Enhances the Secretion of Interleukin-4 in Mast Cells through the Phosphatase and Tensin Homolog/p38/Nuclear Factor-kappaB Pathway. PLoS One. 11:e01488212016. View Article : Google Scholar : PubMed/NCBI
14	Kandere-Grzybowska K, Kempuraj D, Cao J, Cetrulo CL and Theoharides TC: Regulation of IL-1-induced selective IL-6 release from human mast cells and inhibition by quercetin. Br J Pharmacol. 148:208–215. 2016. View Article : Google Scholar
15	Schuliga M: NF-kappaB signaling in chronic inflammatory airway disease. Biomolecules. 5:1266–1283. 2015. View Article : Google Scholar : PubMed/NCBI
16	Ooko E, Kadioglu O, Greten HJ and Efferth T: Pharmacogenomic characterization and isobologram analysis of the combination of ascorbic acid and curcumin-two main metabolites of Curcuma longa-in cancer cells. Front Pharmacol. 8:382017. View Article : Google Scholar : PubMed/NCBI
17	Chearwae W, Anuchapreeda S, Nandigama K, Ambudkar SV and Limtrakul P: Biochemical mechanism of modulation of human P-glycoprotein (ABCB1) by curcumin I, II and III purified from Turmeric powder. Biochem Pharmacol. 68:2043–2052. 2004. View Article : Google Scholar : PubMed/NCBI
18	Jagetia GC and Rajanikant GK: Curcumin stimulates the antioxidant mechanisms in mouse skin exposed to fractionated γ-irradiation. Antioxidants (Basel). 4:25–41. 2015. View Article : Google Scholar : PubMed/NCBI
19	Chin KY: The spice for joint inflammation: Anti-inflammatory role of curcumin in treating osteoarthritis. Drug Des Devel Ther. 10:3029–3042. 2016. View Article : Google Scholar : PubMed/NCBI
20	Deka SJ, Mamdi N, Manna D and Trivedi V: Alkyl cinnamates induce protein kinase C translocation and anticancer activity against breast cancer cells through induction of the mitochondrial pathway of apoptosis. J Breast Cancer. 19:358–371. 2016. View Article : Google Scholar : PubMed/NCBI
21	Xu J, Yang H, Zhou X, Wang H, Gong L and Tang C: Bisdemethoxycurcumin suppresses migration and invasion of highly metastatic 95D lung cancer cells by regulating E-cadherin and vimentin expression, and inducing autophagy. Mol Med Rep. 12:7603–7608. 2015. View Article : Google Scholar : PubMed/NCBI
22	Gordon ON, Luis PB, Ashley RE, Osheroff N and Schneider C: Oxidative transformation of demethoxy- and bisdemethoxycurcumin: Products, mechanism of formation, and poisoning of human topoisomerase IIα. Chem Res Toxicol. 28:989–996. 2015. View Article : Google Scholar : PubMed/NCBI
23	Ramezani M, Hatamipour M and Sahebkar A: Promising Anti-tumor properties of bisdemethoxycurcumin: A naturally occurring curcumin analogue. J Cell Physiol. Jan 11–2017.(Epub ahead of print). PubMed/NCBI
24	Xu JH, Yang HP, Zhou XD, Wang HJ, Gong L and Tang CL: Role of wnt inhibitory factor-1 in inhibition of bisdemethoxycurcumin mediated epithelial-to-mesenchymal transition in highly metastatic lung cancer 95D cells. Chin Med J (Engl). 128:1376–1383. 2015. View Article : Google Scholar : PubMed/NCBI
25	Li YB, Gao JL, Zhong ZF, Hoi PM, Lee SM and Wang YT: Bisdemethoxycurcumin suppresses MCF-7 cells proliferation by inducing ROS accumulation and modulating senescence-related pathways. Pharmacol Rep. 65:700–709. 2013. View Article : Google Scholar : PubMed/NCBI
26	Haukvik T, Bruzell E, Kristensen S and Tønnesen HH: A screening of curcumin derivatives for antibacterial phototoxic effects studies on curcumin and curcuminoids. XLIII. Pharmazie. 66:69–74. 2011.PubMed/NCBI
27	Guo LY, Cai XF, Lee JJ, Kang SS, Shin EM, Zhou HY, Jung JW and Kim YS: Comparison of suppressive effects of demethoxycurcumin and bisdemethoxycurcumin on expressions of inflammatory mediators in vitro and in vivo. Arch Pharm Res. 31:490–496. 2008. View Article : Google Scholar : PubMed/NCBI
28	Kim AN, Jeon WK, Lee JJ and Kim BC: Up-regulation of heme oxygenase-1 expression through CaMKII-ERK1/2-Nrf2 signaling mediates the anti-inflammatory effect of bisdemethoxycurcumin in LPS-stimulated macrophages. Free Radic Biol Med. 49:323–331. 2010. View Article : Google Scholar : PubMed/NCBI
29	Sun J and Nan G: The mitogen-activated protein kinase (MAPK) signaling pathway as a discovery target in stroke. J Mol Neurosci. 59:90–98. 2016. View Article : Google Scholar : PubMed/NCBI
30	Blackwell TS, Blackwell TR and Christman JW: Impaired activation of nuclear factor-kappaB in endotoxin-tolerant rats is associated with down-regulation of chemokine gene expression and inhibition of neutrophilic lung inflammation. J Immunol. 158:5934–5940. 1997.PubMed/NCBI